AZD1152 is primarily used in the field of oncology as a potent inhibitor of Aurora B kinase, an enzyme critical for cell division. Its application focuses on targeting and disrupting the growth of cancer cells, particularly in hematologic malignancies such as acute myeloid leukemia (AML). By inhibiting Aurora B kinase, it induces cell cycle arrest and promotes apoptosis in cancerous cells, making it a promising candidate for cancer therapy. Clinical studies have explored its efficacy in combination with other chemotherapeutic agents to enhance treatment outcomes. Additionally, its role in overcoming drug resistance in certain cancers is under investigation, offering potential for improved therapeutic strategies.